The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Desensitization Protocols and Their Outcome
Abstract
Summary: In the last decade, transplantation across previously incompatible barriers has increasingly become popular because of organ donor shortage, availability of better methods of detecting and characterizing anti-HLA antibodies, ease of diagnosis, better understanding of antibody-mediated rejection, and the availability of effective regimens. This review summarizes all manuscripts published since the first publication in 2000 on desensitized patients and discusses clinical outcomes including acute and chronic antibody-mediated rejection rate, the new agents available, kidney paired exchange programs, and the future directions in sensitized patients. There were 21 studies published between 2000 and 2010, involving 725 patients with donor-specific anti-HLA antibodies (DSAs) who underwent kidney transplantation with different desensitization protocols. All studies were single center and retrospective. The patient and graft survival were 95% and 86%, respectively, at a 2-year median follow-up. Despite acceptable short-term patient and graft survivals, acute rejection rate was 36% and acute antibody-mediated rejection rate was 28%, which is significantly higher than in nonsensitized patients. Recent studies with longer follow-up of those patients raised concerns about long-term success of desensitization protocols. The studies utilizing protocol biopsies in desensitized patients also reported higher subclinical and chronic antibody-mediated rejection. An association between the strength of DSAs determined by median fluorescence intensity values of Luminex single-antigen beads and risk of rejection was observed. Two new agents, bortezomib, a proteasome inhibitor, and eculizumab, an anti-complement C5 antibody, were recently introduced to desensitization protocols. An alternative intervention is kidney paired exchange, which should be considered first for sensitized patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wolfe, R. A., Ashby, V. B., Milford, E. L., Ojo, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,371
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
Solez, K., Colvin, R. B., Racusen, L. C., Haas, M., Sis, B., Mengel, M., Halloran, P. F., Baldwin, W., Banfi, G., Collins, A. B., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02159.x · Cited by 1,857
Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin
Kazatchkine, M. D., & Kaveri, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejmra993360 · Cited by 1,209
Solez, K., Colvin, R., Racusen, L., Sis, B., Halloran, P., Birk, P., Campbell, P., Cascalho, M., Collins, A., Demetris, A., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01688.x · Cited by 1,082
Racusen, L. C., Colvin, R. B., Solez, K., Mihatsch, M. J., Halloran, P. F., Campbell, P. M., Cecka, M. J., Cosyns, J., Demetris, A. J., Fishbein, M. C., et al. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00072.x · Cited by 1,060
Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor
Samuelsson, A., Towers, T. L., & Ravetch, J. V. (2001) · Science · doi:10.1126/science.291.5503.484 · Cited by 1,053
Comparison of Survival Probabilities for Dialysis Patients vs Cadaveric Renal Transplant Recipients
Port, F. K. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510110079036 · Cited by 825
Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation
Lefaucheur, C., Loupy, A., Hill, G. S., Andrade, J., Nochy, D., Antoine, C., Gautreau, C., Charron, D., Glotz, D., & Suberbielle-Boissel, C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009101065 · Cited by 789
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C.-H., Peng, A., Villicana, R., & Jordan, S. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707894 · Cited by 692
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Pescovitz, M. D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01288.x · Cited by 625
Cited by
Tait, B. D., Süsal, C., Gebel, H. M., Nickerson, P. W., Zachary, A. A., Claas, F. H. J., Reed, E. F., Bray, R. A., Campbell, P., Chapman, J. R., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e31827a19cc · Cited by 787
Chadban, S. J., Ahn, C., Axelrod, D. A., Foster, B. J., Kasiske, B. L., Kher, V., Kumar, D., Oberbauer, R., Pascual, J., Pilmore, H. L., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003136 · Cited by 738
IgG endopeptidase in highly sensitized patients undergoing transplantation
Jordan, S. C., Lorant, T., Choi, J., Kjellman, C., Winstedt, L., Bengtsson, M., Zhang, X., Eich, T., Toyoda, M., Eriksson, B.-M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612567 · Cited by 377
Choi, J., Aubert, O., Vo, A., Loupy, A., Haas, M., Puliyanda, D., Kim, I., Louie, S., Kang, A., Peng, A., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14228 · Cited by 355
Muduma, G., Odeyemi, I., Smith-Palmer, J., & Pollock, R. F. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0292-y · Cited by 35
Metadata
- Authors
- Marfo, K., Lu, A., Ling, M., & Akalin, E.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2011-04
- Volume
- 6
- Issue
- 4
- Pages
- 922-936
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2116180543
- Cited by
- 272
- References
- 44
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Desensitization Protocols and Their Outcome. https://app.cochat.ai/papers/10.2215/cjn.08140910
- The paper
- Marfo, K., Lu, A., Ling, M., & Akalin, E. (2011). Desensitization Protocols and Their Outcome. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.08140910
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.